Infertility is medically described as the inability of a woman to become pregnant after nine months of unprotected sexual intercourse (or without using any birth control pills). According to the NHS, U.K., around 1 in 7 couples have problems conceiving, which is around 4 million people. A common cause behind infertility among women is problems with ovulation. According to several medical practitioners, lack of ovulation can result from polycystic ovary syndrome, thyroid problems (both overactive thyroid glands and underactive thyroid glands hamper ovulation), and premature ovarian failure in women. In addition, pelvic or cervical surgery, thinner cervical mucus, fibroids (non-cancerous growth around wombs), and endometriosis can be the reasons for infertility among women. Furthermore, overuse of non-steroidal anti-inflammatory drugs, chemotherapy, neuroleptic medicines, spironolactone, and illegal drugs such as marijuana and cocaine may cause problems in ovulation among women.

Infertility among men is caused by poor quality of sperms and semen, injury to the testicles (caused by testicular cancer, testicular surgery, etc.), ejaculation disorders, and overuse of medications such as sulfasalazine and anabolic steroids. Common diagnostic examinations include blood test, ultrasound scan, chlamydia test, and laparoscopy (semen analysis for infertility testing among men).

The global infertility drugs market is primarily driven by a rise in cases of infertility among couples across the world, rise in rate of diagnosis and treatment of infertility, and development in health care infrastructure. However, stringent regulatory conditions and intellectual property rights law for infertility drugs are anticipated to hamper the growth of global infertility drugs market. Nevertheless, on-going clinical trials on infertility drugs, increase in research and development expenditure, and major mergers and acquisitions among key companies are projected to provide the global infertility drugs market attractive opportunities in the coming years.

The global infertility drugs market can be segmented based on drug class, end-user, drug type, distribution channel, and region. In terms of drug class, the market can be classified into ovulatory stimulants, selective estrogen receptor modulators (SERMs), biguanides, dopamine agonists, tricyclic antidepressants, and others. Based on end-user, the global infertility drugs market can be classified into male and female. In terms drug type, the global infertility drugs market can be segmented into branded and generic. Based on distribution channel, the global infertility drugs market can be divided into hospital pharmacies, retail pharmacies and drug stores, and others.

In terms of region, the global infertility drugs market can be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America held a leading share of the global infertility drugs market in 2017, owing to a highly developed pharmaceutical industry, high rate of diagnosis and treatment of infertility, well-established health care infrastructure, and presence of major players in the region. In Europe, Germany, France, and the U.K. accounted for a major share of the infertility drugs market in 2017.The market in Italy and Spain is expected to expand at a significant growth rate during the forecast period. Highly developed health care industry, high rate of diagnosis and treatment of infertility, and participation of small companies in the market are the key factors that contributed to the significant market share of Germany, France, and the U.K. in 2017.

In Asia, China and Japan held a dominant share of the infertility drugs market in 2017. The infertility drugs market in India is estimated to expand at a significant CAGR in the near future, owing to the developing healthcare industry, presence of well-established domestic players, and intense competition between domestic and international players in the country. An underdeveloped health care industry and lack of awareness about infertility drugs are likely to hamper the infertility drugs market in Latin America and Middle East & Africa during the forecast period.

Key companies operating in the infertility drugs market include Pfizer, Takeda Pharmaceutical Company Limited, F. Hoffmann-La Roche Ltd, Merck, and Eli Lilly.

The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.

The study is a source of reliable data on:

  • Market segments and sub-segments
  • Market trends and dynamics
  • Supply and demand
  • Market size
  • Current trends/opportunities/challenges
  • Competitive landscape
  • Technological breakthroughs
  • Value chain and stakeholder analysis

The regional analysis covers:

  • North America (U.S. and Canada)
  • Latin America (Mexico, Brazil, Peru, Chile, and others)
  • Western Europe (Germany, U.K., France, Spain, Italy, Nordic countries, Belgium, Netherlands, and Luxembourg)
  • Eastern Europe (Poland and Russia)
  • Asia Pacific (China, India, Japan, ASEAN, Australia, and New Zealand)
  • Middle East and Africa (GCC, Southern Africa, and North Africa)

The report has been compiled through extensive primary research (through interviews, surveys, and observations of seasoned analysts) and secondary research (which entails reputable paid sources, trade journals, and industry body databases). The report also features a complete qualitative and quantitative assessment by analyzing data gathered from industry analysts and market participants across key points in the industry’s value chain.

A separate analysis of prevailing trends in the parent market, macro- and micro-economic indicators, and regulations and mandates is included under the purview of the study. By doing so, the report projects the attractiveness of each major segment over the forecast period.

Highlights of the report:

  • A complete backdrop analysis, which includes an assessment of the parent market
  • Important changes in market dynamics
  • Market segmentation up to the second or third level
  • Historical, current, and projected size of the market from the standpoint of both value and volume
  • Reporting and evaluation of recent industry developments
  • Market shares and strategies of key players
  • Emerging niche segments and regional markets
  • An objective assessment of the trajectory of the market
  • Recommendations to companies for strengthening their foothold in the market   

Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.

.